rapidmicrobio.com (RPID) - Long-Term Indebtedness

Symbol and logo of brand Rapid Micro Biosystems Inc. (RPID)

Rapid Micro Biosystems (RPID) automates sterility testing for pharmaceuticals, creating synergy with major pharmaceutical behemoths. The market price confirmed by the chart on GURU.Markets, where long-term debt stands at 0.02, complements the business outlook. However, industry conservatism and reliance on a limited number of customers create risks. Stability is ensured by stringent FDA standards and the complexity of switching IT validation, which block the emergence of competitors.

RPID (Rapid Micro Biosystems, Inc.) Company Long-Term Debt history from 07/04/2022 to 10/28/2026

Metric breakdowns and analytics for Rapid Micro Biosystems, Inc. (RPID)

- price and consensus price forecast:
Stock Price Rapid Micro Biosystems Inc.|RPID - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Rapid Micro Biosystems|RPID - Total Company Value
- book capitalization data:
Equity per Share Rapid Micro Biosystems|RPID - Company Book Value|Market-to-Book Ratio rapidmicrobio.com|RPID - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Coefficient Rapid Micro Biosystems|RPID - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Rapid Micro Biosystems Inc.|RPID - Company Aggregate Debts|Debts to Net Assets Rapid Micro Biosystems|RPID - Company Long-Term Debts|Company Current Liabilities Rapid Micro Biosystems
General company analysis:RPID (Rapid Micro Biosystems)
Mass-produced product of rapidmicrobio.com

Rapid Micro Biosystems (RPID) is scaling the production of automated testing systems, utilizing debt capital to support operational activities. This long-term corporate debt measures the volume of strategic obligations, determining financial leverage and the degree of dependence on creditors. Amid declining laboratory investments and cash flow gaps, this indicator becomes a critical marker of solvency. The stability of the chart confirms the resilience of the quotes to debt risks.

Competitor analysis for Rapid Micro Biosystems

Company Long-Term Debts abbott.com ABT|Company Long-Term Debts TMO|GEHC: Long-Term Indebtedness|Company Long-Term Debt Mettler-Toledo International Inc.|WAT (Waters Technologies) - Company Long-Term Indebtedness|Company Long-Term Debt TECH (Bio-Techne Corporation)|Long-Term Debt BRKR|AZTA (Azenta) - Company Long-Term Debt|Long-Term Debt Volume Varex Imaging Corp VREX|Company Long-Term Liabilities Semler Scientific Corp (SMLR)|Amount of Long-Term Liabilities Butterfly Corp BFLY|Company Long-Term Debts MLAB (Mesa Laboratories, Inc.)|QSI - Long-Term Debt Volume|NNOX (Nano-X) - Company Long-Term Debts|Company Long-Term Liabilities Quanterix Corp.|MASS - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings CV|Company Long-Term Debt MXCT (MaxCyte, Inc.)|Company Long-Term Liabilities seer.bio (SEER)|HYPR: Company Long-Term Debts|Long-Term Debt FONAR Corp. FONR|Daxor Corp. (DXR) - Company Long-Term Debts|MDAI - Company Long-Term Indebtedness|organovo.com - Company Long-Term Debts|aclarion.com (ACON) - Long-Term Debt Volume|Company Long-Term Debts AKYA|Company Long-Term Liabilities ThermoGenesis Holdings, Inc.|Company Long-Term Debts TLIS|Company Long-Term Debts TTOO (T2 Biosystems Inc)